A randomised, single-blind, placebo- controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes - Keymeulen, B; van Maurik, A; Inman, D (2020)
Diabetologia